ICU Medical ( (ICUI) ) has released its Q4 earnings. Here is a breakdown of the information ICU Medical presented to its investors.
ICU Medical, Inc. is a global leader in the development and sale of innovative medical products, specializing in infusion systems and critical care products for hospital and home care settings. In its latest earnings report, ICU Medical announced a revenue increase to $629.8 million for the fourth quarter of 2024, up from $587.9 million in the same period the previous year. Despite a GAAP net loss of $23.8 million, the company reported an adjusted diluted earnings per share of $2.11, reflecting a strong performance in adjusted metrics. Key highlights include a rise in adjusted EBITDA to $105.5 million, driven by increased revenues in consumables and vital care products. The company also noted higher IV solutions revenues due to a U.S. market shortage. Looking ahead, ICU Medical projects a GAAP net loss for fiscal year 2025 but anticipates adjusted EBITDA to range between $395 million and $425 million. The company remains optimistic about its strategic initiatives, including an IV Solutions joint venture expected to close in the second quarter of 2025.